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Abstract 
 
Matrix Metalloproteinase and Carbonic Anhydrase Detection Based on 
19F MRI and Fluorescence 
 
Sophia Katherine Beyer, M.A. 
The University of Texas at Austin, 2018 
 
Supervisor: Emily Que 
 
Zinc metalloproteins are heavily involved in a wide variety of human diseases,1 
such as rheumatoid arthritis, periodontitis, and cancer. Matrix metalloproteinase (MMP) 
and carbonic anhydrase (CA) are two zinc containing enzymes that are seen as attractive 
biomarkers for a multitude of pathological conditions, due to their overexpression in these 
diseases as well as their role in the spread and metastasis of cancer cells. Therefore, we 
focused on creating probes designed to track the location and relative concentration of 
matrix metalloproteinase and carbonic anhydrase through fluorescence and 19F MRI. In the 
first project, an inhibitor and a set of fluorophores were synthesized to bind to MMPs and 
display a “turn on” signal. In the second project, a probe was designed to detect MMP 
activity through 19F MRI. Finally, in the third project, a probe was created to detect CA 
activity via 19F MRI. Here, we describe the synthesis and characterization of these probes 
and report preliminary UV and fluorescence response along with 19F NMR T1 and T2 
relaxivity. 
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I. INTRODUCTION 
Zinc is necessary for proper function and activity of a wide variety of enzymes.2 With 
binding sites in tetrahedral or trigonal bipyramidal geometry, zinc is responsible for maintaining 
structure and stability while also participating in chemical catalysis.2 One example of zinc 
containing enzymes are matrix metalloproteinases (MMPs). MMPs are zinc containing 
endopeptidases that degrade different components of the extracellular matrix.3 These enzymes are 
expressed during tissue remodeling processes such as wound healing, uterine and mammary 
involution, and embryonic development.3 However, they are also known to be overexpressed in 
multiple pathological conditions including rheumatoid arthritis, periodontitis, and tumor cell 
invasion and metastasis.3 A second example of zinc containing enzymes is carbonic anhydrase 
(CA). CA is a lyase enzyme that catalyzes the reversible conversion of carbon dioxide to 
bicarbonate and it is responsible for transporting bicarbonate ions across membranes and blood 
during such processes as respiration.4 CA is also known to be vital to the process of tumor 
progression and metastasis.5 Therefore, we designed small molecule probes to track the location 
and relative concentration of these zinc metalloenzymes through fluorescence and 19F MRI.  
Fluorescence microscopy is the most widely used imaging technique in biological studies, 
particularly when monitoring cellular systems.6 This is due to its high sensitivity, high 
spatiotemporal resolution, and simple experimental procedure.6 To specifically target MMPs, 
fluorophores and an inhibitor with hydroxamic acid functionality were designed and synthesized 
(Scheme 1). Hydroxamic acids have been used as the zinc-binding group of choice for MMP 
targeting and inhibition.7 The fluorophores were based off of a known compound, N,N-
dimethylaminopthalimide (DMAP)8 that is not fluorescent in aqueous environments and 
fluorescent in hydrophobic environments including enzyme active sites4 (Figure 1A). The 
 2 
fluorescent probes were synthesized with different linker lengths in order to compare binding 
efficiency. 
 
Figure 1: (A) Representation of fluorescent “turn on” response of probes 5.1 – 5.4 in the 
hydrophobic environment of the MMP active site. MBG represents the metal binding group. (B) 
Design strategy for probe 25, which will be cleaved by MMP creating two fractions of lower 
molecular mass resulting in an increased 19F MRI signal. (C) Design strategy for hypoxia-induced 
Cu2+ based probe 38, which results in an increased 19F MRI signal when bound to CA. 
 
In addition to fluorescence, we also used 19F magnetic resonance imaging (MRI) as a 
method to track MMP location and activity (Scheme 2). MRI is a noninvasive technique that 
provides important medical information on deep tissues that cannot be acquired through other 
methods.9 Due to its visualization of deep regions of human and animal bodies, MRI is one of the 
most successful imaging techniques for diagnosis.6 This probe was designed with three basic 
components: a metal coordination site, a fluorine tag, and a peptide sequence that is specifically 
cleaved by MMPs. The metal coordination serves as a paramagnetic imaging reporter.10 The intact 
probe will be silent to magnetic resonance (MR) imaging until cleaved by MMP, when the probe 
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will be altered into a fragment with a different relaxivity, thus creating a high contrast 
enhancement.10 When the probe gets cleaved, this results in two smaller fragments. This decrease 
in molecular mass is expected to cause a significant decrease in the 19F relaxation rate, creating a 
signal in MRI.11 We chose to use a fluorine tag due to the preferable MR properties of the 19F 
nucleus and minimal signal in the human body, as compared to 1H MR imaging.12  
A fluorine tag was also used in our final probe, designed to track CA location through 19F 
MRI (Scheme 3). This probe was designed with a metal chelator, a fluorine tag, a PEG linker, and 
a sulfonamide functionality. The sulfonamide group was chosen as a selective target for CA, due 
to its significant CA binding ability.13 Sulfonamides bind in a tetrahedral geometry of the Zn(II) 
ion in a deprotonated state, with the nitrogen atom coordinating to the zinc.14 The PEG linker 
connects the sulfonamide group to the fluorine tag, which is then connected to the Cu(II) 
coordination complex 1,4,7-triazacyclononane (TACN). CA (especially CAIX) is selectively 
expressed in hypoxic tumors and promotes tumor cell survival and invasion in hypoxic 
microenvironments.5 These probes should function via signal accumulation on cells that over 
express CAIX. PEG linkers of different lengths were synthesized to determine optimal distance 
between the sulfonamide moiety and the bulky TACN group. The synthesis and characterization 
of these metalloenzyme probes is discussed here.     
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II. RESULTS AND DISCUSSION 
 
 
Chapter 1: MMP Targeted Inhibitor and Fluorophores 
 
To construct fluorophores specific for MMPs, four probes containing varying linker 
lengths were synthesized. A known inhibitor for MMP was also synthesized as a control molecule 
(Scheme 1).  Detailed synthesis of these probes can be found in the “Materials and Methods” 
section. 
 
 
Scheme 1. Conditions: (a) HCHO, H2, Pd/C, MeOH, O.N. (b) 120 °C, O.N. (c) glycine (n=1), 
gamma-aminobutyric acid (n=2), 5-aminovaleric acid (n=4), TEA, toluene, reflux (d) O-
benzylhydroxylamine, EDC, DIPEA, CHCl3, O.N. (e) H2, Pd/C, MeOH, O.N. (f) 4-iodophenol, 
NaOH, 40 °C (g) SOCl2, reflux (h) hexamethyldistannane, Pd(PPh3)4, toluene, reflux (i) 3-
iodophenylacetonitrile, Pd(PPh3)4, toluene, reflux 
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Once the four fluorophores were synthesized (compounds 5.1, 5.2, 5.3, and 5.4, n = 1, 2, 
3, and 4, respectively), solvent studies were performed. The UV-Vis absorbance and fluorescence 
intensity were measured for each fluorophore, at concentrations of 1 – 10 µM. Probe 5.2 had a 
greater absorbance in the non-polar solvents, as expected. However, probe 5.1 showed a larger 
absorbance in chloroform and methanol, probe 5.3 had the highest absorbance in DMSO, and 
probe 5.4 had the highest absorbance in chloroform. Overall, toluene, chloroform, and DMSO 
provided larger fluorophore absorbance values when compared to methanol and water. Figure 2 
provides a comparison of the molar absorptivity values of each of the four fluorophores in the five 
solvents tested. Figure 3 and Figure 4 show representative absorbance and fluorescence spectra 
(respectively), one for each fluorophore (2 µM), in the different solvents. Table 1 includes all of 
the numerical data collected during the solvent study, including the wavelength of maximum 
absorbance, the molar absorptivity, and the emission wavelengths for the four fluorophores in the 
five tested solvents. The excitation wavelength was the same as the λmax. There is a bathochromic 
shift in λmax and λem for all molecules upon going from non-polar to more polar solvents due to 
solvent relaxation.16 More notably, the shift in wavelength is accompanied by a decrease in 
fluorescence intensity in polar solvents, which is due to a twisted intramolecular charge transfer 
(TICT) state.17, 18 
 
Figure 2: Solvent polarity study with fluorophores. Each fluorophore absorbance was monitored 
in five different solvents: toluene, chloroform, DMSO, methanol, and water (in order of increasing 
polarity). 
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Figure 3: Graphs showing fluorophore UV-Vis absorbances in toluene, chloroform, DMSO, 
methanol, and water to compare absorbance values in different solvent polarities. Each fluorophore 
was measured at a concentration of 2 µM in solution and the measurements were taken at room 
temperature.  
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Figure 4: Graphs showing fluorophore fluorescence intensities in toluene, chloroform, DMSO, 
methanol, and water to compare absorbance values in different solvent polarities. Each fluorophore 
was measured at a concentration of 2 µM in solution and the measurements were taken at room 
temperature.  
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Probe   toluene chloroform DMSO methanol water 
5.1 
λmax (nm) 384 400 400 395 418 
ε (M-1cm-1) 4320 5895 3904 5654 4094 
λem (nm) 475 495 508 545 590 
5.2 
λmax (nm) 386 400 400 395 418 
ε (M-1cm-1) 27913 12570 9933 9725 9394 
λem (nm) 484 500 513 550 595 
5.3 
λmax (nm) 390 400 400 400 420 
ε (M-1cm-1) 16513 22863 24900 20384 16635 
λem (nm) 480 500 515 550 600 
5.4 
λmax (nm) 384 396 400 400 420 
ε (M-1cm-1) 10448 12514 12061 10057 10451 
λem (nm) 465 487 510 550 595 
 
Table 1: Summation of solvent study data, showing the wavelength of maximum absorbance, the 
molar absorptivity, and the excitation and emission wavelengths for the four fluorophores in the 
five tested solvents: toluene, chloroform, DMSO, methanol, and water. 
   
Following the solvent studies, fluorescence of the four fluorophores was monitored as 
bovine CA (bCA) was introduced to the system. The fluorophores were tested with bCA while 
awaiting the arrival of the MMP enzyme, as well as a means to become familiarized with the UV 
and fluorimeter instrumentation and techniques. An interaction of the fluorophores with bCA was 
not expected and is not seen in Figure 5. The fluorescence intensity was monitored while different 
concentrations of fluorophore and bCA were added to the cuvette. Figure 5A-C show the 
fluorescence spectra for probe 5.1-5.3  in the absence (purple) and presence of 1 equiv bCA (red). 
The graphs show no increase in fluorescence in the presence of bCA that suggests the lack of 
interaction between the probe and the protein. A final test was performed with the fluorophore 
concentrations being significantly higher than the bCA concentrations (Figure 5D). Results were 
as expected; the higher equivalents of probe added to bCA additions did not alter the fluorescence 
of the fluorophores. 
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Figure 5: (A-C) Fluorescence spectra of probes 5.1 to 5.3 (5 µM) in the absence (purple) and 
presence (red) of 1 equiv. bCA in HEPES buffer (pH 7.2) at room temperature. (D) Fluorescence 
spectra of 5 µM bCA with higher equivalence of probe 5.4 (4, 8, and 12 equivalents) to study 
binding with CA. The spectra for probe 5.4 only are shown as dotted lines. 
 
To further test the lack of binding and interaction of the fluorophores with bCA, we 
performed the 4-nitrophenylacetate (NPA) assay. NPA assay tests the activity of bCA by following 
the hydrolysis of 4-nitrophenylacetate to 4-nitrophenolate ion that absorbs at 400nm. NPA assay 
performed with compounds 5.1 and 5.4 (Figure 6) showed neither of the compounds decreased 
the activity of bCA that supports the fact that these molecules indeed do not inhibit CA.  There 
were some unexpected results however, in the fact that they increased bCA activity to greater than 
100% (compound 5.1 increased to 123% bCA activity and compound 5.4 increased to 119% bCA 
activity).   
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Figure 6: NPA assay with compounds 5.1 and 5.4. These assays were performed in 50mM HEPES 
buffer with 100 mM KNO3, pH 7.2 at room temperature.  
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Chapter 2: MMP Detection Through 19F MRI 
A probe that detects the presence of MMP upregulation via 19F MRI was synthesized, along 
with two control probes, one without the TACN functionality and one with a “pre-cleaved” amino 
acid linker (Scheme 2). The idea behind this design was to have a probe silent to MR initially, 
until the peptide sequence is cleaved by MMP at which point the molecular mass of the probe will 
significantly decrease, causing a decrease in 19F relaxation rate, resulting in a MR signal.10 Cu2+ 
will be used as the paramagnetic reporter. The synthetic scheme is shown below. Detailed 
synthesis of these probes can be found in the “Materials and Methods” section. 
 
       
 12 
 
Scheme 2. Conditions: (a) P-anisaldehyde, HCl, H2O (b) tert-butyl 2-bromoacetate, KOtBu, 
THF/DMF, 45 °C (c) TsCl, DMAP, 0 °C, DCM (d) NaN3, DMF (e) HOAc, H2O, 40 °C (f) F9OH, 
PPh3, DIAD, THF (g) TIS, TFA, H2O (h) TsCl, 1,2-dibromoethane, K2CO3, H2O, PhMe, NaOH, 
Bn4NBr (i) NaOH (j) bromoethylacetate, NaHCO3, CHCl3 (k) 3-bromoprop-1-yne, K2CO3, ACN 
(l) 22, ascorbic acid, copper sulfate, degassed H2O, DCM (m) peptide (prepared via peptide 
synthesizer), DIPEA, HATU, DMF 
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The synthesized molecules were characterized via NMR. The T1 and T2 data is summarized 
in Table 2 below. T1 and T2 data was first gathered for compound 26 on the 60 MHz NMR. The 
compound was not completely soluble in 1 mL D2O, so 1 mL ACN was added; thus the NMR data 
was collected in a solution of 1:1 D2O:ACN.  The T1 and T2 values were determined to be 1.44 
seconds and 1.437 seconds, respectively, which resulted in sharp peaks. The 19F NMR spectrum 
of this compound can be seen below (Figure 7). Next, T1 and T2 data was collected for compound 
25, which was soluble in 100% D2O. The T1 analysis showed very small, broad peaks on both the 
60 MHz NMR and the 400 MHz, which suggested aggregation. This result lead to DLS and DOSY 
NMR analysis, both of which confirmed the presence of aggregates. Compound 25 was then 
dissolved in 600 µL of 100 mM ammonium acetate buffer (pH 5.05), in order to have a better 
understanding of peptide charge while performing these experiments. 120 µL of D2O (20%) was 
added to the solution to allow for further NMR analysis. The 60 MHz NMR showed T1 and T2 
values of 122 ms and 19.2 ms respectively; since these values are significantly different from one 
another, the peaks were very broad. The same analysis was performed on the 400 MHz NMR, 
which resulted in T1 and T2 values of 253 ms and 6.75 ms, respectively. This data supports the 
significant difference between the T1 and T2 values seen on the 60 MHz NMR. The 19F NMR 
spectrum for compound 25 can be seen below (Figure 8). It is possible that compound 25 
experiences temperature dependence; perhaps the compounds in solution are arranging in such a 
way that beta sheets are forming around the fluorine groups, quenching any possible signal. NMR 
analysis should be performed at different temperatures. The same T1/T2 analysis was then 
performed on compound 28, in 80:20 100 mM ammonium acetate buffer (pH 5.05):D2O. The 60 
MHz NMR provided T1 and T2 values of 245.5 ms and 12.79 ms, respectively, while the 400 MHz 
NMR reported T1 and T2 values of 248.75 ms and 13.125 ms, respectively. The two NMR 
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instruments showed the same significant difference between the T1 and T2 values and thus both 
conveyed broad peaks during this analysis. Once again, this lead to the question of aggregation. 
Further studies need to be performed to conclude how the molecules are interacting 
intramolecularly and intermolecularly in solution. Figures 9 – 12 below show the T1 and T2 
correlation analysis performed on 60 MHz NMR in ammonium acetate buffer (with 20% D2O) for 
compounds 25 and 28.        
 
Compound Solvent Instrument T1 (ms) T2 (ms) 
26 50:50 ACN : D2O 60 MHz 1440 1437 
25 100% D2O 60 MHz too broad too broad 
25 80:20 ammonium acetate buffer : D2O 60 MHz 122 19.2 
25 80:20 ammonium acetate buffer : D2O 400 MHz 253 6.75 
28 80:20 ammonium acetate buffer : D2O 60 MHz 75.705 12.79 
34.42 
28 80:20 ammonium acetate buffer : D2O 400 MHz 248.75 13.125 
 
Table 2: Table summarizing the T1/T2 analysis of compounds 25, 26, and 28. These values were 
collected on either a 60 MHz benchtop NMR or a 400 MHz NMR, at room temperature.  
  
 
Figure 7: 19F NMR of compound 26 in deuterium oxide at room temperature at 400 MHz. 
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Figure 8: 19F NMR of compound 25 in deuterium oxide at room temperature at 400 MHz. 
 
 
 
Figure 9: T1 NMR analysis of compound 25, performed in ammonium acetate buffer on the 60 
MHz benchtop NMR. 
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Figure 10: T2 NMR analysis of compound 25, performed in ammonium acetate buffer on the 60 
MHz benchtop NMR. 
 
 
 
Figure 11: T1 NMR analysis of compound 28, performed in ammonium acetate buffer on the 60 
MHz benchtop NMR. 
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Figure 12: T2 NMR analysis of compound 28, performed in ammonium acetate buffer on the 60 
MHz benchtop NMR. 
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Chapter 3: CA Detection Through 19F MRI 
Two preliminary probes of varying linker lengths were built to detect CA upregulation 
through 19F MRI (Scheme 3). The purpose of the sulfonamide functionality is to selectively bind 
the probe to CA and allow for probe accumulation at the tumor site.13 Detailed synthesis of these 
probes can be found in the “Materials and Methods” section.  
There was a major issue encountered when performing the synthesis of compounds 33 and 
36: the coupling of compound 23 to compounds 32 and 35 was not successful through the use of 
HATU as a coupling agent (determined by the 8% yield). Mass spectroscopy revealed that the 
majority of compound 23 was left unreacted, even after the reaction was stirred for two days. This 
situation was remedied by replacing HATU with PyBOP (with all other conditions left the same).  
After this change was made, the yield was significantly increase to 48%.  
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Scheme 3. Conditions: (a) TEA, TsCl, DCM (b) NaN3, EtOH, 80 °C (c) 4-(2-
aminoethyl)benzenesulfonamide, K2CO3, DMF, 80 °C (d) H2, Pd/C, MeOH (e) 2b, PyBOP, 
DIPEA, DMF (f) TIS, TFA, H2O (g) copper acetate, H2O 
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To study the interaction of compound 33 with carbonic anhydrase, an NPA assay was 
performed (Figure 13A). The bCA and compound 33 concentrations were both 2 µM. The NPA 
was in excess (125 µM). The compound did not show significant binding, decreasing the bCA 
activity to only 86%. This data was reproducible. Following this, a study was done to compare 
bCA activity with different ratios of compound 33 to bCA (Figure 13B). The results were 
inconclusive, which suggested that the compound is slower to bind to bCA than NPA. Therefore, 
these assays were followed up by NPA assays performed after an incubation period, where 
compound 33 was incubated with bCA at room temperature for 30 minutes and 60 minutes before 
NPA was added (Figures 14A and 14B, respectively). The 30 minute and 60 minute incubation 
periods resulted in bCA activity decreasing to 70% and 85%, respectively.  
 
 
Figure 13: (A) NPA assay with compound 33 performed in 50mM HEPES buffer with 100 mM 
KNO3, pH 7.2 at room temperature. (B) NPA assay performed with varying ratios of bCA to 
compound 33, performed in 50mM HEPES buffer with 100 mM KNO3, pH 7.2 at room 
temperature.  
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Figure 14: (A) NPA assay after 30 minute room temperature incubation period of compound 33 
and bCA, performed in 50mM HEPES buffer with 100 mM KNO3, pH 7.2. (B) NPA assay after 
60 minute room temperature incubation period of compound 33 and bCA, performed in 50mM 
HEPES buffer with 100 mM KNO3, pH 7.2. (C) NPA assay after 60 minute incubation period of 
compound 33 and bCA at 37 °C, performed in 50mM HEPES buffer with 100 mM KNO3, pH 7.2. 
 
Due to the fact that incubating the probe with bCA before the NPA assay was not showing 
a significant decrease in bCA activity, incubation at 37 °C for 60 minutes was also explored 
(Figure 14C). These results were not as expected, as the bCA activity increased to 138%. After 
these results, the binding was analyzed through a 5-(dimethylamino)naphthalene-1-sulfonamide 
(DNSA) assay. DNSA is not fluorescent on its own but forms a highly fluorescent complex with 
CA and binds to CA well due to its sulfonamide functionality.19 Therefore, fluorescence was 
monitored to detect DNSA binding to the CA active site. After the DNSA was bound to CA, our 
probes were added to the solution and a decrease in fluorescence was expected due to the probes 
binding stronger to CA than DNSA, thus kicking DNSA out of the CA active site and becoming 
non-fluorescent. Figure 15 shows standard DNSA additions to a solution of HEPES (1 mL) and 
bCA (0.25 µM); the additions were made in 0.25 µM increments, for a total concentration of 2.5 
µM. Once the DNSA was added, compound 33 was added to the solution in 0.05 µM increments 
(Figure 16). The total probe concentration reached 0.5 µM, 2 equivalents as compared to the bCA. 
The results were as expected, as the tryptophan fluorescence increased (340 nm) while the DNSA 
fluorescence decreased (470 nm). This assay showed some binding of the probe to bCA, however 
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not in a significant quantity; the DNSA intensity decreased from 134 a.u. to 115 a.u. A second 
DNSA trial was performed on compound 33 (Figure 17). This trial was a repeat of trial 1, however 
this time 12 equivalents of compound 33 were added, for a total probe concentration of 3 µM. This 
trial provided different results from the previous trial, with the DNSA intensity decreasing with 
the additions of probe (124 a.u. to 40 a.u.), showing probe binding to bCA. The results of these 
two trials are different due to the change in probe equivalents added (2 equivalents versus 12 
equivalents); these results show that a significant concentration of compound 33 is necessary in 
order to see binding to bCA.  
 
 
Figure 15: Standard DNSA additions to bCA in 50mM HEPES buffer with 100 mM KNO3, pH 
7.2, at room temperature. Concentration of DNSA increased from 0 µM to 2.5 µM.  
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Figure 16: DNSA assay with compound 33 in 50mM HEPES buffer with 100 mM KNO3, pH 7.2, 
at room temperature. Concentration of probe increased from 0 µM to 0.5 µM. Concentration of 
DNSA was 2.5 µM.  
 
 
Figure 17: DNSA assay with compound 33 in 50mM HEPES buffer with 100 mM KNO3, pH 7.2, 
at room temperature. Concentration of probe increased from 0 µM to 3 µM. Concentration of 
DNSA was 2.5 µM.  
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was hypothesized that a longer PEG chain would reduce the steric effects by allowing the TACN 
functionality to be farther from the enzyme active site. Once synthesized, an NPA assay was 
performed on compound 37 (Figure 18A) with bCA and probe concentrations of 2 µM and NPA 
in excess. The probe decreased bCA activity to 24% which suggests significant binding. A second 
NPA assay was then performed, addressing different ratios of probe to bCA (Figure 18B). During 
this assay, the bCA concentration was held constant at 2 µM while the probe concentration was 
changed from 2 µM to 10 µM to 20 µM, which resulted in bCA activities of 80%, 51%, and 38% 
respectively. These results were not expected, as the 2 µM probe concentration resulted in a much 
higher percent bCA activity than the first NPA assay had indicated. This lead us to believe that 
compound 37 was degrading in solution.   
 
 
Figure 18: (A) NPA assay with compound 37 in 50mM HEPES buffer with 100 mM KNO3, pH 
7.2, at room temperature. (B) NPA assay comparing different ratios of compound 37 to bCA (1:1, 
5:1, and 10:1), performed in 50mM HEPES buffer with 100 mM KNO3, pH 7.2, at room 
temperature.  
 
 
Finally, an NPA assay was performed on compound 38 (Figure 19), again with bCA and 
probe concentrations of 2 µM. The bCA activity was only decreased to 96%, which shows no 
binding to bCA. Further proof of lack of binding of compounds 37 and 38 to bCA was evident 
after performing binding studies on a 36 well plate monitoring UV absorbance at 405 nm (Figure 
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20). The probe concentrations were increased from 0 µM to 5 µM. No binding can be observed 
from these plots and no aggregation was found during a DLS analysis of compound 37. Based on 
these results, we think that compounds 37 and 38 degrade quickly in solution. One possible way 
to remedy this problem would be to store dry aliquots of compounds 37 and 38, rather than storing 
them in solution (even storing them at -20 °C did not prevent this fast degradation in solution). It 
is also speculated that hydrophobic effects are negatively affecting the binding of these probes to 
CA. Since the fluorine moiety is hydrophobic, the molecules in solution may be arranging 
themselves in such a way that the hydrophobic (fluorine) side of the molecules are surrounded by 
the hydrophilic PEG chains. This bulky arrangement would then make it difficult for the 
sulfonamide groups to enter the CA active site. These results require further investigation.   
 
 
Figure 19: NPA assay with compound 38 performed in 50mM HEPES buffer with 100 mM KNO3, 
pH 7.2, at room temperature. 
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Figure 20: Binding studies monitoring the binding of compounds 37 and 38 with bCA over 2700 
seconds, increasing the probe concentrations from 0 µM to 5 µM. This was performed on a 36 well 
plate measuring absorbance at 405 nm at room temperature.  
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III. MATERIALS AND METHODS 
 
General 
 
All solvents and chemicals were purchased from Sigma-Aldrich, Acros and Fisher Sci. and used 
as received. High pressure liquid chromatography (HPLC) was carried out on a Biotage Isolera 
One. The 1H and 19F NMR spectroscopic measurements were conducted using a 400 MHz 
AGILENT NMR spectrometer. NMR samples were prepared in CD3CN, CDCl3, D2O, or CD3OD 
and chemical shifts are reported in ppm. Electrospray Ionization Mass Spectrometry (ESI-MS) 
was performed on an Agilent 6130 Mass Spectrometer equipped with a UV-Vis detector. 
Spectroscopic studies were performed using an Agilent Cary 60 UV-Vis Spectrophotometer and 
an Agilent Cary Eclipse Fluorescence Spectrophotometer. Peptide synthesis was performed using 
a CEM Liberty Blue Automated Microwave Peptide Synthesizer. 
Synthesis 
 
 
 
 
Compound 1: 4-nitrophthalic acid (420 mg, 2 mmol) was dissolved in methanol (120 mL). 
Formaldehyde (12 mL, 436 mmol) and palladium on carbon (160 mg, 1.5 mmol) were added to 
the flask. Finally, hydrogen gas was introduced to the system and the mixture was stirred overnight 
at RT. The reaction mixture was filtered through a celite pad and washed with methanol (2 x 20 
mL). The methanol was concentrated in vacuo and this resulted in a yellow solid (0.2319 g, 56% 
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yield). 1H NMR (400 MHz, Methanol-d4) δ 7.83 (s, 1H), 6.85 (s, 1H), 6.74 (s, 1H), 3.35 (s, 3H), 
3.03 (s, 5H).  
 
Compound 2: Compound 1 (1.4445 g, 6.9 mmol) was put into a sublimation apparatus and heated 
at 120 °C overnight. Product was a bright yellow solid (0.1857 g, quantitative yield). 1H NMR 
(400 MHz, Methanol-d4) δ 7.77 (s, 1H), 7.16 (s, 1H), 7.13 (d, J = 8.7 Hz, 1H), 3.17 (s, 6H). 
 
Compound 3.1: Compound 2 (70 mg, 0.36 mmol) was combined with glycine (27 mg, 0.36 mmol) 
in toluene (4 mL). Triethylamine (0.1 mL, 0.72 mmol) was added and the solution was refluxed 
overnight at 115 °C. The product was allowed to cool to RT, the solvent was evaporated, and the 
crude mixture was taken up in DI water (50 mL). The crude product was extracted with ethyl 
acetate (3 x 15 mL). The organic layers were washed with brine (1 x 45 mL), dried over sodium 
sulfate, and concentrated in vacuo. Silica column chromatography (gradient, 97:3 DCM:MeOH) 
gave a yellow solid (35.1 mg, 37% yield).  
 
Compound 3.2: Compound 2 (70 mg, 0.36 mmol) was combined with beta-alanine (32.608 mg, 
0.36 mmol) in toluene (4 mL). Triethylamine (0.1 mL, 0.72 mmol) was added and the solution 
was refluxed overnight at 115 °C. The product was allowed to cool to RT, the solvent was 
evaporated, and the crude mixture was taken up in DI water (50 mL). The crude product was 
extracted with ethyl acetate (3 x 15 mL). The organic layers were washed with brine (1 x 45 mL), 
dried over sodium sulfate, and concentrated in vacuo. Product was purified through PLC (gradient, 
99:1 DCM:MeOH) and resulted in a yellow solid (81.6 mg, 85% yield). 
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Compound 3.3: Compound 2 (70 mg, 0.36 mmol) was combined with gamma-aminobutyric acid 
(37.7 mg, 0.36 mmol) in toluene (4 mL). Triethylamine (0.1 mL, 0.72 mmol) was added and the 
solution was refluxed overnight at 115 °C. The product was allowed to cool to RT, the solvent was 
evaporated, and the crude mixture was taken up in DI water (50 mL). The crude product was 
extracted with ethyl acetate (3 x 15 mL). The organic layers were washed with brine (1 x 45 mL), 
dried over sodium sulfate, and concentrated in vacuo. Product was purified through PLC (gradient, 
99:1 DCM:MeOH) and resulted in a yellow solid (75 mg, 74% yield).  
 
Compound 3.4: Compound 2 (70 mg, 0.36 mmol) was combined with 5-aminovaleric acid (43 mg, 
0.36 mmol) in toluene (4 mL). Triethylamine (0.1 mL, 0.72 mmol) was added and the solution 
was refluxed overnight at 115 °C. The product was allowed to cool to RT, the solvent was 
evaporated, and the crude mixture was taken up in DI water (50 mL). The crude product was 
extracted with ethyl acetate (3 x 15 mL). The organic layers were washed with brine (1 x 45 mL), 
dried over sodium sulfate, and concentrated in vacuo. Silica column chromatography (gradient, 
97:3 DCM:MeOH) gave a yellow solid (78.5 mg, 74% yield).  
 
Compound 4: Compound 3 (78.5 mg, 0.27 mmol) was taken up in dry chloroform, under nitrogen. 
O-benzylhydroxylamine (86.2 mg, 0.54 mmol), EDC (77.6 mg, 0.405 mmol), and DIPEA (0.19 
mL, 1.08 mmol) were added to the flask and the reaction mixture stirred overnight at room 
temperature under nitrogen. The crude product was washed with DI water (2 x 20 mL) and the 
aqueous layers were washed with chloroform (2 x 20 mL). The combined organic layers were 
washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo. Silica 
column chromatography (gradient, 1:9 MeOH:DCM) resulted in a yellow oil (83.8 mg, 78% yield).  
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Compound 5: Compound 4 (83.8 mg, 0.212 mmol) was dissolved in MeOH (10 mL). Four 
nitrogen/vacuum cycles were performed on the flask. Pd/C (50.5 mg, 0.475 mmol) was added to 
the solution and four additional nitrogen/vacuum cycles were performed. Finally, H2 gas was 
introduced to the flask via balloon. The reaction mixture was stirred overnight at room 
temperature. The mixture was then filtered through a celite pad, washed with MeOH (3 x 50 mL), 
and concentrated in vacuo. Silica column chromatography (gradient, 75:25 EtOAc:hexanes 
followed by 5:95 MeOH:DCM) resulted in a yellow oil (6.4 mg, 10% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.63 (d, J = 8.5 Hz, 1H), 7.26 (s, 1H), 7.06 (s, 1H), 6.78 (d, J = 10.9 Hz, 1H), 3.65 
(s, 3H), 3.11 (s, 6H), 2.42 (s, 1H), 2.36 (s, 1H), 1.83 (s, 1H), 1.66 (d, J = 24.7 Hz, 5H), 1.25 (s, 
1H). 
 
 
 
Compound 6: 3-chloropropionic acid (246 mg, 2.27 mmol) was combined with 4-iodophenol (500 
mg, 2.27 mmol). 4.8 M NaOH (1.14 mL) was added dropwise and the reaction stirred at 40 °C 
overnight. The crude product was taken up in DI water (10 mL) and extracted with EtOAc (3 x 10 
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mL). The aqueous layer was acidified with concentrated HCl and again the product was extracted 
with EtOAc (1 x 10 mL). The combined organic layers were dried over MgSO4 and concentrated 
in vacuo which resulted in a beige powder (0.1128 g, 17% yield). 1H NMR (400 MHz, 
Acetonitrile-d3) δ 7.68 – 7.57 (m, 4H), 6.81 – 6.72 (m, 4H), 6.36 (s, 7H), 4.31 (dtd, J = 7.5, 6.1, 
1.4 Hz, 3H), 4.20 (t, J = 6.1 Hz, 4H), 3.83 – 3.73 (m, 2H), 2.83 – 2.71 (m, 6H), 2.70 – 2.58 (m, 
3H), 2.49 (td, J = 6.0, 1.1 Hz, 0H), 2.03 – 1.93 (m, 1H), 1.29 (s, 1H). 
 
Compound 7: Compound 6 (0.1045 g, 0.358 mmol) was dissolved in thionyl chloride (0.624 mL, 
8.59 mmol). The solution was heated to reflux (at 80 °C) for thirty minutes. The reaction was then 
cooled to RT, diluted with diethyl ether (5 mL), and concentrated in vacuo. The resulting residue 
was azeotroped with diethyl ether (3 x 10 mL) and concentrated in vacuo, forming a brown oil. 
The crude product was carried onto the next step. 
 
Compound 8: Compound 7 (0.11 g, 0.358 mmol) was dissolved in dry chloroform (12 mL) under 
nitrogen. O-benzylhydroxylamine (0.114 g, 0.716 mmol), EDC (0.103 g, 0.537 mmol), and DIPEA 
(0.25 mL, 1.432 mmol) were added and the reaction stirred overnight at RT. The reaction mixture 
was washed with DI water (2 x 12 mL). Remaining product was extracted from the combined 
aqueous layers with chloroform (2 x 24 mL). The combined organic layers were washed with brine 
(1 x 20 mL), dried with MgSO4, and concentrated in vacuo over silica gel. Flash chromatography 
(1:99 MeOH:DCM to 15:85 MeOH:DCM) gave a yellow solid (29.5 mg, 21% yield). 1H NMR 
(400 MHz, Chloroform-d) δ 8.30 (s, 1H), 7.55 (s, 2H), 7.38 (s, 5H), 6.78 – 6.49 (m, 2H), 4.93 (s, 
2H), 4.30 – 4.09 (m, 2H), 2.54 (s, 2H). 
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Compound 9: Compound 8 (30 mg, 0.076 mmol) was dissolved in dry toluene (2 mL) under 
nitrogen. Hexamethyldistannane (0.02 mL, 0.0855 mmol) was added to the reaction, followed by 
Pd(PPH3)4 (4.4 mg, 0.0038 mmol). The reaction was stirred at RT for ten minutes then heated to 
reflux (115 °C) for 40 minutes. The reaction mixture was cooled to RT, diluted with EtOAc (10 
mL), and filtered. The filtrate was washed with 1 mM PBS buffer at pH 7 (1 x 10 mL) and brine 
(1 x 10 mL), dried with Na2SO4, and concentrated in vacuo which resulted in a brown oil (2.21 
mg, 66% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.50 (s, 1H), 7.71 – 7.41 (m, 5H), 6.85 (t, 
J = 17.8 Hz, 3H), 4.92 (s, 3H), 4.20 (s, 4H), 2.56 (s, 2H), 0.27 (s, 9H). 
 
Compound 10: Compound 9 (0.0212 g, 0.05 mmol) was dissolved in dry toluene (1 mL) under 
nitrogen. 3-iodophenylacetonitrile (0.0123 g, 0.05 mmol) and Pd(PPH3)4 (0.0035 g, 0.003 mmol) 
were added to the mixture and the reaction stirred for ten minutes at RT. The reaction was then 
heated to reflux (115 °C) for 24 hours, cooled back down to RT, and diluted with EtOAc (20 mL). 
The product was washed with 1 mM PBS buffer at pH 7 (1 x 20 mL) and brine (1 x 20 mL). The 
organic layer was dried with Na2SO4 and concentrated in vacuo which resulted in a yellow product 
(13.4 mg, 71% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.77 – 7.59 (m, 2H), 7.62 – 7.52 (m, 
1H), 7.56 – 7.43 (m, 3H), 7.48 – 7.37 (m, 1H), 7.40 – 7.23 (m, 1H), 6.99 (dd, J = 8.9, 2.8 Hz, 1H), 
5.96 (s, 1H), 5.57 (s, 1H), 4.94 (s, 0H), 4.39 – 4.18 (m, 1H), 3.86 – 3.71 (m, 5H), 3.75 – 3.62 (m, 
1H), 2.78 – 2.67 (m, 1H), 2.06 (s, 0H), 1.92 – 1.78 (m, 4H), 1.31 – 1.23 (m, 2H), 0.92 – 0.82 (m, 
0H), 0.07 (s, 1H). 
 
Compound 11: Compound 10 (10.8 mg, 0.028 mmol) was dissolved in dry MeOH (1.2 mL). Four 
nitrogen/vacuum cycles were performed on the flask. Pd/C (6.67 mg, 0.063 mmol) was added to 
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the solution and four additional nitrogen/vacuum cycles were performed. Finally, H2 gas was 
introduced to the flask via balloon. The reaction mixture was stirred overnight at room 
temperature. The mixture was then filtered through a celite pad, washed with MeOH (3 x 50 mL), 
and concentrated in vacuo. Flash chromatography (75:25 EtOAc:hexanes) gave a yellow product 
(3.3 mg, 40% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H), 7.57 – 7.31 (m, 9H), 4.95 
(s, 2H), 4.26 (s, 2H), 2.60 (s, 2H). 
 
 
 
Compound 12: Pentaerythritol (25 g, 183.6 mmol) was dissolved in DI water (180 mL). The 
solution was heated to 70 °C. The solution was cooled to RT and concentrated HCl (1 mL) was 
added to the solution. P-anisaldehyde (1 mL, 8.22 mmol) was added to the solution and the reaction 
stirred until precipitation. The remaining P-anisaldehyde (22.5 mL, 184.9 mmol) was added to the 
mixture dropwise via addition funnel and the reaction stirred for three hours. The crude mixture 
was washed with 0.1 M Na2CO3 (1 x 500 mL) and ether (1 x 500 mL). Product was concentrated 
in vacuo.  
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Compound 13: Compound 12 (10 g, 39.33 mmol) was put into a 3-neck flask containing a stir bar 
and chilled in a water and ice bath. Once cooled, dry DMF (100 mL) was added to the flask 
dropwise. Potassium tert-butoxide, 1.7 M (20% wt.%) solution in THF (25 mL, 206.97 mmol) was 
added dropwise, followed by tert-butyl 2-bromoacetate (7.6 mL, 51.47 mmol). The reaction was 
removed from the ice bath and refluxed at 65 °C for two days. The reaction was cooled to RT, 
filtered, and concentrated in vacuo. The product was taken up in 200 mL EtOAc and washed with 
DI water (1 x 200 mL). Remaining product was extracted from the aqueous layer with DCM (2 x 
200 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. 
Silica column chromatography (10:1 hexanes:EtOAc to 2:1 hexanes:EtOAc) resulted in an oil (9 
g, 62% yield). 
 
Compound 14: Compound 13 (9 g, 24.43 mmol) was combined with DMAP (4.48 g, 36.64 mmol) 
and dissolved in DCM (100 mL). The reaction was cooled to 0 °C. TsCl (6.98 g, 36.64 mmol) was 
added and the reaction warmed up to RT and stirred overnight. The product was washed with 
NaHCO3 (2 x 50 mL) and brine (3 x 50 mL), dried over sodium sulfate, and concentrated in vacuo. 
Silica column chromatography (10:1 hexanes:EtOAc to 4:1 hexanes:EtOAc) resulted in an oil (8 
g, 62% yield). 
 
Compound 15: Sodium azide (1.5 g, 22.95 mmol) was combined with compound 14 (8 g, 15.3 
mmol) and dissolved in DMF (80 mL). Flask was flushed with nitrogen and heated to 120 °C for 
two days. The mixture was cooled to RT, taken up in Milli-Q water (160 mL), and extracted with 
DCM (3 x 160 mL). The combined organic layers were washed with brine (1 x 200 mL), dried 
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over sodium sulfate, and concentrated in vacuo. Silica column chromatography (20:3 
hexanes:EtOAc) resulted in an oil (3 g, 50% yield).  
 
Compound 16: Compound 15 (3 g, 7.6 mmol) was dissolved in 4:1 HOAc:H2O (25 mL) and stirred 
at 40 °C for three hours. Reaction brought back to RT and concentrated in vacuo. Sodium 
bicarbonate (50 mL) in water (50 mL) was used to neutralize the reaction. The product was 
extracted with EtOAc (3 x 25 mL), dried over sodium sulfate, and concentrated in vacuo. Silica 
column chromatography (10:1 hexanes:EtOAc to 2:1 hexanes:EtOAc) resulted in an oil (1.96 g, 
93% yield).  
 
Compound 17: PPh3 (6.36 g, 24.26 mmol) was dissolved in dry THF (35 mL) and cooled to 0 °C. 
DIAD (4.88 g, 24.26 mmol) was added to the flask along with additional THF (5 mL). The reaction 
was removed from ice and stirred for 20 minutes. Nitrogen was introduced to the system. 
Compound 16 (2.2261 g, 8.086 mmol) was dissolved in dry THF (40 mL) and added in small 
batches to the reaction. C4HF9O (3.38 mL, 24.26 mmol) was added to the reaction. The solution 
was removed from nitrogen and stirred for three days at RT. The solution was concentrated in 
vacuo over silica gel. Silica column chromatography (pure hexanes to 20:1 hexanes:DCM) resulted 
in an opaque oil product (3.314 g, 58% yield).  
 
Compound 18: Compound 17 (2 g, 2.8 mmol) was combined with TIS (0.26 mL, 1.27 mmol) and 
Milli-Q water (0.26 mL, 14.44 mmol). The reaction was cooled to 0 °C and TFA (10 mL, 130.59 
mmol) was added. The reaction stirred overnight and was allowed to warm to RT. The solution 
was concentrated in vacuo and azeotroped with DCM (3 x 10 mL). The crude product was 
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concentrated in vacuo over silica gel. Silica column chromatography (pure DCM to 8:1 
DCM:MeOH with 0.5% HOAc) resulted in the product (0.9146 g, 50% yield).    
 
 
Compound 19: Synthesized by Dr. Meng Yu. 
 
Compound 20: Synthesized by Dr. Meng Yu. 
 
Compound 21: Compound 20 (1.2 g, 9.29 mmol) was added to a flask under nitrogen. Dry 
chloroform (30 mL) was added to compound 20 and the reaction was placed over an ice bath. 
Sodium bicarbonate (1.56 g, 18.58 mmol) was added to the solution, followed by tert-butyl 
bromoacetate (3.17 mL, 21.47 mmol) dropwise. More chloroform (50 mL) was added and the 
reaction stirred under nitrogen overnight at RT. The crude product was concentrated in vacuo over 
celite. Flash chromatography (pure water with formic acid to 30:70 ACN:water) resulted in the 
pure product. 
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Compound 22: Compound 21 (10 mg, 0.028 mmol) was dissolved in dry acetonitrile (5 mL). 
Potassium carbonate (9.665 mg, 0.07 mmol) was added and the reaction stirred for 20 minutes. 
The reaction was placed over an ice bath and 3-bromoprop-1-yne (0.028 mL, 0.3424 mmol) was 
added dropwise (under nitrogen). The ice bath was removed and the reaction stirred at RT for two 
days. LCMS confirmed product formation. 
 
 
 
Compound 23: Compound 22 (0.247 g, 0.6245 mmol) was combined with compound 18 (0.341 g, 
0.5204 mmol) in dry DCM (5 mL). Ascorbic acid (0.0206 g, 0.1041 mmol) and copper sulfate (6.5 
mg, 0.02602 mmol) were combined and dissolved in degassed water (5 mL). The water solution 
was added to the DCM solution and stirred in a glove box overnight at RT. Added 0.05 equivalents 
more of copper sulfate and 0.2 equivalents more of ascorbic acid; reaction stirred another night. 
The solution was washed with chloroform (3 x 20 mL). The combined organic layers were dried 
over sodium sulfate and concentrated in vacuo over celite. Flash chromatography resulted in pure 
product (340 mg, 62% yield).  
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Compound 24: Peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) (0.117 g, 0.035 mmol) was added to 
a filtered syringe. Dry DCM (4 mL) was added and the resin was allowed to swell for ten minutes. 
The DCM was ejected. Compound 23 (55.17 mg, 0.0525 mmol), DIPEA (0.04877 mL, 0.280 
mmol), and HATU (26.62 mg, 0.07 mmol) were combined in DMF (5 mL) and stirred for ten 
minutes under nitrogen. The DMF solution was pulled up into the filtered syringe containing the 
peptide and the reaction mixed on a shaker overnight. The solution was ejected and washed with 
DMF (3 x 5 mL), DCM (3 x 5 mL), and MeOH (3 x 5 mL). Product dried on lyophilizer. Product 
was confirmed through LCMS.  
 
Compound 25: Compound 24 (0.117 g, 0.0867 mmol) was combined with TFA (5 mL, 65.3 
mmol), TIS (0.26 mL, 1.27 mmol) and Milli-Q water (0.26 mL, 14.44 mmol) in a filtered syringe. 
The reaction was mixed on a shaker for three hours. The solution was concentrated in vacuo. Flash 
chromatography (45:55 ACN:water) resulted in a solid (8 mg, 9% yield). 19F NMR (376 MHz, 
Deuterium Oxide) δ -70.68. 
 
 
 
Compound 26: Peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) (0.140 g, 0.049 mmol) was added to 
a filtered syringe. Dry DCM (4 mL) was added and the resin was allowed to swell for ten minutes. 
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The DCM was ejected. Compound 18 (64.21 mg, 0.098 mmol), DIPEA (0.03414 mL, 0.196 
mmol), and HATU (37.26 mg, 0.098 mmol) were combined in DMF (3 mL) and stirred for ten 
minutes under nitrogen. The DMF solution was pulled up into the filtered syringe containing the 
peptide and the reaction mixed on a shaker overnight. The solution was ejected and washed with 
DMF (3 x 5 mL), DCM (3 x 5 mL), and MeOH (3 x 5 mL). Product dried on lyophilizer. The 
crude product was combined with TFA (5 mL, 65.3 mmol), TIS (0.26 mL, 1.27 mmol) and Milli-
Q water (0.26 mL, 14.44 mmol) in a filtered syringe. The reaction was mixed on a shaker for three 
hours. The solution was concentrated in vacuo. Flash chromatography (0:100 to 40:60 to 100:0 
ACN:water) resulted in a solid (13 mg, 9% yield). 19F NMR (376 MHz, Deuterium Oxide) δ -
70.53. 
 
Compound 27: Peptide (Gly-Pro-Leu-Gly) (0.117 g, 0.0351 mmol) was added to a filtered syringe. 
Dry DCM (4 mL) was added and the resin was allowed to swell for ten minutes. The DCM was 
ejected. Compound 23 (44.3 mg, 0.04212 mmol), 2,4,6-collidine (0.01827 mL, 0.1404 mmol), and 
PyAOP (36.6 mg, 0.0702 mmol) were combined in DMF (3 mL) and stirred for ten minutes under 
nitrogen. The DMF solution was pulled up into the filtered syringe containing the peptide and the 
reaction mixed on a shaker overnight. The solution was ejected and washed with DMF (3 x 5 mL), 
DCM (3 x 5 mL), and MeOH (3 x 5 mL). Product dried through lyophilization and taken onto the 
next step.  
 
Compound 28: Compound 27 was combined with TFA (5 mL, 65.3 mmol), TIS (0.26 mL, 1.27 
mmol) and Milli-Q water (0.26 mL, 14.44 mmol) in a filtered syringe. The reaction was mixed on 
a shaker for three hours. The solution was concentrated in vacuo. Flash chromatography (0:100 to 
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40:60 to 100:0 ACN:water) resulted in a solid (14.3 mg, 27% yield). 19F NMR (376 MHz, 
Deuterium Oxide) δ -71.41 (d, J = 29.3 Hz). 
 
 
 
Compound 29: Tetraethylene glycol (3 g, 15.45 mmol) was dissolved in dry DCM (40 mL). TEA 
(4.31 mL, 30.89 mmol) was added and the solution was cooled to 0 °C. P-toluenesulfonylchloride 
(8.84 g, 46.35 mmol) was added portion-wise to the reaction. The solution was allowed to warm 
to RT and stirred overnight under nitrogen. The solution was washed with saturated sodium 
bicarbonate (3 x 40 mL) and dried over sodium sulfate. The organic layers were concentrated in 
vacuo. Silica column chromatography (50:50 hexanes:DCM) resulted in an oil (6.1027 g, 79% 
yield).  
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Compound 30: Compound 29 (6.1027 g, 12.14 mmol) was dissolved in ethanol (50 mL) and cooled 
to 0 °C, under nitrogen. Sodium azide (0.789 g, 12.14 mmol) was measured out with a plastic 
spatula and added to the reaction over 20 minutes. The reaction was heated to reflux (80 °C) and 
stirred overnight, under nitrogen. The reaction was cooled to RT and taken up in DCM (50 mL) 
and washed with saturated sodium bicarbonate (1 x 100 mL). The organic layer was dried over 
sodium sulfate and concentrated in vacuo. Silica column chromatography (75:25 hexanes:EtOAc) 
resulted in a yellow oil (1.1871 g, 26% yield).  
 
Compound 31: Compound 30 (22.3 mg, 0.0599 mmol), 4-(2-aminoethyl)benzenesulfonamide (10 
mg, 0.0499 mmol), and potassium carbonate (10.34 mg, 0.075 mmol) were combined in dry DMF 
(3 mL) under nitrogen. The reaction was heated to 80 °C overnight. The reaction mixture was 
cooled to RT and concentrated in vacuo. The crude product was taken up in DI water (5 mL) and 
extracted with EtOAc (3 x 5 mL). The organic layers were washed with brine (1 x 5 mL), dried 
over sodium sulfate, and concentrated in vacuo. Silica prep plate chromatography (1:1:1 
MeOH:acetone:DCM) resulted in an oil (8.4 mg, 35% yield).  
 
Compound 32: Compound 31 (8.4 mg, 0.0209 mmol) was diluted with dry MeOH (2 mL). Four 
vacuum/nitrogen cycles were performed on the reaction flask. Pd/C (5 mg, 0.0469 mmol) was 
added to the reaction and four additional vacuum/nitrogen cycles were preformed. H2 gas was 
introduced to the reaction via balloon and the reaction stirred overnight at RT. The mixture was 
filtered through a celite pad, rinsed with MeOH (3 x 50 mL), and concentrated in vacuo, resulting 
in product (11 mg, quantitative yield).  
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Compound 33: Compound 32 (11 mg, 0.0293 mmol) was combined with compound 23 (33.86 mg, 
0.0322 mmol) and HATU (22.43 mg, 0.059 mmol) and the flask was dried under vacuum for 30 
minutes. Dry DMF (1 mL) and dry DCM (1 mL) were added to the flask, followed by DIPEA 
(0.02042 mL, 0.1172 mmol). The reaction stirred overnight at RT under nitrogen. The reaction 
was concentrated in vacuo and then taken up in DI water (5 mL). The product was extracted with 
DCM (3 x 5 mL) and the combined organic layers were dried over sodium sulfate and concentrated 
in vacuo. Silica prep plate chromatography (5:95 MeOH:DCM) resulted in product (4.3 mg, 10% 
yield). 1H NMR (400 MHz, Methanol-d4) δ 8.51 (d, J = 23.1 Hz, 2H), 8.46 – 8.32 (m, 1H), 8.26 
(d, J = 13.6 Hz, 1H), 7.87 – 7.70 (m, 2H), 7.42 (d, J = 8.0 Hz, 2H), 1.47 (q, J = 4.3, 3.0 Hz, 18H). 
19F NMR (376 MHz, Methanol-d4) δ -71.27 – -71.56 (m). 
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Compound 34: 17-azido-3,6,9,12,15-pentaoxaheptadecyl 4-methylbenzenesulfonate (27.6 mg, 
0.0599 mmol) was added to a flask containing 4-(2-aminoethyl)benzenesulfonamide (10 mg, 
0.0499 mmol) and potassium carbonate (10.34 mg, 0.075 mmol) in dry THF (3 mL). The reaction 
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was heated to 80 °C and stirred overnight under nitrogen. The reaction was cooled to RT and 
concentrated in vacuo. Product was taken up in DI water (5 mL) and extracted with EtOAc (3 x 5 
mL). The combined organic layers were washed with brine (1 x 15 mL), dried over sodium sulfate, 
and concentrated in vacuo. Silica prep plate chromatography (1:1:1 MeOH:acetone:DCM) gave 
pure product (8.4 mg, 29% yield).  
 
Compound 35: Compound 34 (19 mg, 0.04 mmol) was diluted with dry MeOH (1 mL) and dry 
DCM (1 mL). Four vacuum/nitrogen cycles were performed on the reaction flask. Pd/C (9.22 mg, 
0.09 mmol) was added to the reaction and four additional vacuum/nitrogen cycles were preformed. 
H2 gas was introduced to the reaction via balloon and the reaction stirred overnight at RT. The 
mixture was filtered through a celite pad, rinsed with MeOH (3 x 50 mL), and concentrated in 
vacuo, resulting in product (17 mg, 94% yield).  
 
Compound 36: Compound 35 (6.9 mg, 0.015 mmol) was combined with compound 23 (17.34 mg, 
0.0164 mmol) and PyBOP (15.62 mg, 0.03 mmol) and the flask was dried under vacuum for 30 
minutes. Dry DMF (2 mL) was added to the flask, followed by DIPEA (0.01045 mL, 0.06 mmol). 
The reaction stirred overnight at RT under nitrogen. The reaction was concentrated in vacuo and 
then taken up in DI water (5 mL). The product was extracted with DCM (3 x 5 mL) and the 
combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash 
chromatography (76:24 MeOH:water) resulted in pure product (10.7 mg, 48% yield).  
 
Compound 37: Compound 36 was combined with TIS (0.26 mL, 1.27 mmol) and Milli-Q water 
(0.26 mL, 14.44 mmol). The reaction was cooled to 0 °C and TFA was added (5 mL, 65.3 mmol). 
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The reaction was allowed to warm to RT and stirred overnight. The solution was azeotroped with 
DCM (3 x 5 mL) and concentrated in vacuo. Flash chromatography (0:100 to 75:25 to 100:0 
MeOH:water) resulted in pure product (13.9 mg, quantitative yield). 
 
Compound 38: Compound 37 (13.9 mg, 0.01004 mmol) was dissolved in Milli-Q water (1 mL). 
The pH was adjusted to 7 with 1 M NaOH (1 drop). Copper acetate (2.21 mg, 0.01105 mmol) was 
added to the solution and the reaction stirred at RT for three hours. Flash chromatography (0:100 
to 45:55 to 75:25 to 100:0 NH4OAc:ACN) resulted in pure product (4.6 mg, 32% yield). 1H NMR 
(400 MHz, Deuterium Oxide) δ 12.43 (s, 3H), 9.33 – 9.27 (m, 2H), 8.86 (t, J = 7.3 Hz, 2H), 8.55 
(d, J = 7.8 Hz, 2H), 8.28 – 8.17 (m, 4H), 4.28 (s, 2H), 3.65 (s, 4H), 3.52 (s, 21H), 3.30 (s, 4H), 
2.49 (s, 10H). 
 
Solvent Studies: Stock solutions of the fluorophores were prepared as 10 mM solutions in DMSO. 
The probe stock solution (0.3 µL, 0.1 µM) was added to 3 mL of the solvent being studied (either 
chloroform, methanol, DMSO, water, or toluene). The UV-Vis absorbance and fluorescence 
intensity were measured for each fluorophore, at concentrations of 1 – 10 µM. 
 
bCA Binding Studies: Stock solutions of the fluorophores were prepared as 10 mM solutions in 
DMSO. The probe stock solution (5 µM) was added to HEPES buffer (pH 7.2, 500 µL) at room 
temperature. Absorbance and intensity data was collected over a range of concentrations (1 µM – 
5 µM). This was performed without any bCA, as a standard. Then, the experiment was performed 
with bCA; the fluorophore was added first, followed by increasing concentrations of bCA (1 µM 
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– 5 µM) and then vice versa. Finally, this study was performed with 20 µM, 40 µM, and 60 µM 
fluorophore compared to 5 µM bCA. 
 
Peptide Synthesis: Peptides were synthesized through solid-phase peptide synthesis (SPPS). All 
amino acids were F-moc protected and Wang resin was used and supplied in polystyrene beads. 
Following synthesis, the beads were washed with DMF (3 x 10 mL), DCM (3 x 10 mL), and MeOH 
(3 x 10 mL) and dried through lyophilization. Separation of the peptides from the beads was 
accomplished through standard TFA de-protection methods (see above for experimental details).  
 
NPA Assay: Probe stock solutions were prepared as 10 mM DMSO solutions. The CA stock 
solution was prepared as 350 μM solution in 50 mM HEPES with 100 mM KNO3, pH 7.2. The 
NPA stock solution was prepared as 125 mM acetonitrile solution. A typical NPA experiment was 
carried out by adding HEPES (500 μL), then NPA stock solution (1 μL, 250 μM), probe (0.1 μL, 
2.0 μM), and finally CA (2.8 μL, 2.0 μM) to a quartz cuvette. The absorbance was scanned 7 times, 
the interval between each scan was 90 seconds. 
 
DNSA Assay: Probe stock solutions were prepared as 100 μM DMSO solutions. The CA stock 
solution was prepared as a 2 mg/mL solution in 50 mM HEPES, 100 mM KNO3, pH 7.2. The 
DNSA solution was prepared as 1 mM in DMSO. The excitation setting on the fluorimeter was 
280 nm, slit width of 10. The emission was set to 300 – 600 nm, slit width of 10. 1 mL of HEPES 
was added to a quartz cuvette to collect a baseline. CA (3.5 μL, 0.25 μM) was added to the cuvette. 
DNSA (2.5 μL, 2.5 μM) was then added. Finally, probe (0.5 μL, 0.05μM) was added and the 
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emission spectra was measured. Probe was added ten times, for a final concentration of 0.5 μM; 
an emission spectrum was gathered after each addition. 
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IV. APPENDIX 
 
Figure 21: 1H NMR of compound 1.  
 
Figure 22: 1H NMR of compound 2.  
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Figure 23: 1H NMR of compound 5.1. 
 
 
Figure 24: 1H NMR of compound 6. 
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Figure 25: 1H NMR of compound 8. 
 
 
Figure 26: 1H NMR of compound 9. 
 51 
 
Figure 27: 1H NMR of compound 10. 
 
 
Figure 28: 1H NMR of compound 11. 
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Figure 29: 19F NMR of compound 25. 
 
 
Figure 30: 19F NMR of compound 26. 
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Figure 31: 19F NMR of compound 28. 
 
 
Figure 32: 1H NMR of compound 33. 
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Figure 33: 19F NMR of compound 33. 
 
 
Figure 34: 1H NMR of compound 38.  
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Figure 35: Beer’s Law of compound 11.  
 
 
Figure 36: Beer’s Law of compound 33 (trial 1).  
 
 
Figure 37: Beer’s Law of compound 33 (trial 2). 
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Figure 38: Beer’s Law of compound 33 (trial 3). 
 
 
Figure 39: Beer’s Law of compound 37. 
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